Back to search
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Geographic Atrophy
Macular Degeneration
Clinicaltrials.gov:
EU CTIS:
#2022-500747-21-00
Other:
#81201887MDG3002
Interested in this trial?
Email or download this trial
Trials at a glance
Status
Enrolling
Condition
Geographic Atrophy
Macular Degeneration
Trial type
Interventional
Trial phase
Phase 2
Investigational
product
product
JNJ-81201887
Sham Procedure
Age
60+ years old
Biological sex
All
Placebo?
No
Trial start date
September 19, 2024
Trial end date
June 27, 2030
CT.gov ID
#NCT06635148
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Inclusion Criteria:
- Participants who were enrolled and received treatment with JNJ-81201887 or sham in a parent clinical study (81201887MDG2001, 81201887MDG1003)
- Females (women of childbearing potential), male participants, and partners of male participants will not be required to use contraception in this LTE study
- Must sign an informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study. The ICF may be signed by an impartial witness and/or legally designated representative depending on national/local regulations
Exclusion Criteria:
- There are no exclusion criteria for this LTE study
Note: The criteria listed here are only a general guide. To join any trial, you must first have a medical check by a qualified doctor or healthcare professional. They will decide if the trial is a good fit and safe for your health.
Access detailed
information on the trial:
information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2025
